Dr. Gomella on Novel Prostate Cancer Immunotherapies

Video

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies

Leonard G. Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses novel immunotherapies that are available for prostate cancer. The most exciting immunotherapy currently approved for prostate cancer is Provenge because of its very unique nature. Gomella believes that other immunotherapies, such as ipilimumab, may also move into the prostate cancer field.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD